Metabolon Raises Additional $15 Million in Funding

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Metabolon, Inc. , the global leader in metabolomics, announced today that it has raised an additional $15 million in funding from investor Essex Woodlands , a leading healthcare growth equity firm. Essex Woodlands made an initial $15 million investment in Metabolon in August 2016 to further develop and commercialize the company’s pipeline of precision medicine products employing its proprietary metabolomics technology. Proceeds from this additional round of financing have been fully utilized by the company to repurchase and retire certain shares held by existing investors. With those transactions complete, Essex Woodlands’ total investment in Metabolon is now $30 million.

About Essex Woodlands With $2.5 billion under management, Essex Woodlands is one of the largest and oldest growth equity firms pursuing investments in pharmaceuticals, medical devices, healthcare services and healthcare information technology. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing and/or management of over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of over 20 senior investment professionals with offices in Palo Alto, Houston, New York and London. For more information, please see www.ewhv.com .

About Metabolon Metabolon, Inc. is the world’s leading health technology company focused on the use of metabolomics in precision medicine. This powerful tool for assessing health is based on proprietary platforms and informatics that deliver biomarker discoveries, innovative diagnostic tests, and ground-breaking partnerships in genomics-based health initiatives. Metabolon’s expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. Founded in 2000 and headquartered in Research Triangle Park, North Carolina, the company has conducted more than 5,000 independent and collaborative studies, resulting in over 600 peer-reviewed publications. For more information, please visit www.metabolon.com or follow us on LinkedIn or Twitter .

Cautionary Note about Forward-Looking Statements The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove to be incorrect, Metabolon’s results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; the clinical utility of Metabolon’s metabolomic services; Metabolon’s and its distributors’ ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including access, pricing and reimbursement of diagnostic tests; the strength of Metabolon’s intellectual property portfolio; Metabolon’s history of operating losses; whether Metabolon is able to achieve or sustain profitability; its highly competitive industry; its ability to compete effectively; security and privacy risks; and Metabolon’s ability to continue to innovate and provide products and services that are useful to its clients, among other risks, uncertainties and assumptions.

Contact: Robin Fastenau Vice President, Corporate Communications & Investor Relations Metabolon, Inc. 919.595.2201